Actinium achieves fifty percent enrollment in pivotal phase 3 SIERRA trial for Iomab-B
Actinium announced the 75th patient has been treated in the pivotal Phase 3 SIERRA trial of Iomab-B, thus achieving 50 percent patient enrollment for the trial. The 19 active SIERRA trial sites in the U.S. and Canada represent many of the leading bone marrow transplant centers by volume. July 23, 2019